EP11.03. Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Adam Lee
Meta Tag
Speaker Adam Lee
Topic Metastatic NSCLC: Immunotherapy - Retrospective
network meta-analysis
nivolumab plus ipilimumab
immunotherapy-based regimens
metastatic non-small cell lung cancer
tumor programmed death ligand 1
systematic literature review
phase 3 randomized controlled trials
overall survival
progression-free survival
Powered By